New shot could clear teen psoriasis – trial underway
NCT ID NCT07265284
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called picankibart in teenagers aged 12 to 18 with moderate-to-severe plaque psoriasis. Half get the drug, half get a placebo, and researchers check if their skin clears up after 16 weeks. The goal is to see if it's safe and works better than a dummy treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- picankibart (IBI112)
- What this could lead to
- If it works, this could offer a new treatment option for teenagers with stubborn psoriasis, helping clear skin and improve quality of life.
- What could go wrong
- This is still an early-stage trial with only 104 participants, so results may not apply to everyone. As with any drug, there are risks of side effects like infections or allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Children's Hospital Affiliated to Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new gel calm psoriasis Flare-Ups?
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a switch to guselkumab clear stubborn psoriasis?
- Can a new biologic clear stubborn psoriasis?
- Diet and exercise may tame psoriasis in kids — a trial puts it to the test
- Ancient herbal mix put to the test against psoriasis